Superworth

SpyGlass Pharma EPS SGP

Diluted earnings per share by quarter and over the last twelve months, from 2025.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
−$0.59

SpyGlass Pharma's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was −$0.59.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Quarter by quarter

QuarterEndedEPSOn a year earlier
Q2 FY26−$0.59n/a
Q1 FY26−$0.69n/a
Q2 FY25−$3.81n/a
Q1 FY25−$3.96n/a

Against its peers

Companies in Medical - Instruments & Supplies nearest SpyGlass Pharma's size, closest first, today.

CompanyEPS, 12 monthsGrowth
SGPSpyGlass Pharman/m
BVSBioventus$0.77+627% a year
IARTIntegra Lifesciences$0.17
IRMDIradimed$1.87+13% a year
STAAStaar Surgical$0.07
CDRECadre$0.81−14% a year
EYENational Vision$0.61
MOVMovado$1.80+137% a year
LMATLemaitre Vascular$2.85+38% a year
INSPInspire Medical Systems$4.62+132% a year
UFPTUFP Technologies$9.28+8% a year
Peer median$1.30

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on SpyGlass Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.